Boston Partners raised its position in Chemed Corporation (NYSE:CHE – Free Report) by 34.3% during the third quarter, Holdings Channel.com reports. The firm owned 376,995 shares of the company’s stock after buying an additional 96,311 shares during the period. Boston Partners’ holdings in Chemed were worth $190,416,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of CHE. BlackRock Inc. acquired a new position in Chemed in the second quarter worth approximately $691,290,000. First Trust Advisors LP raised its stake in Chemed by 24.7% in the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock worth $89,295,000 after acquiring an additional 46,791 shares during the last quarter. Copeland Capital Management LLC lifted its stake in Chemed by 1.3% in the 3rd quarter. Copeland Capital Management LLC now owns 146,833 shares of the company’s stock valued at $74,162,000 after buying an additional 1,826 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Chemed during the 2nd quarter valued at about $48,255,000. Finally, Caisse de depot et placement du Quebec bought a new stake in Chemed in the 2nd quarter valued at about $44,309,000. 95.85% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Chemed
In other Chemed news, EVP Spencer Lee sold 1,000 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $547.61, for a total value of $547,610.00. Following the completion of the sale, the executive vice president directly owned 12,931 shares of the company’s stock, valued at $7,081,144.91. This trade represents a 7.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin McNamara sold 2,000 shares of the business’s stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the completion of the transaction, the chief executive officer owned 66,418 shares in the company, valued at $34,102,322.10. The trade was a 2.92% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 7,920 shares of company stock worth $4,147,306. Corporate insiders own 3.33% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have recently commented on CHE shares. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada boosted their target price on shares of Chemed from $548.00 to $585.00 and gave the stock a “sector perform” rating in a report on Thursday, October 29th. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and increased their price objective for the company from $520.00 to $620.00 in a report on Wednesday, October 28th. Oppenheimer increased their price objective on Chemed from $590.00 to $625.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Finally, Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $603.00.
Chemed Trading Up 0.9%
CHE stock opened at $551.41 on Friday. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $562.24. The firm has a fifty day moving average price of $519.43 and a 200 day moving average price of $469.94. The firm has a market cap of $7.18 billion, a PE ratio of 26.38, a price-to-earnings-growth ratio of 2.08 and a beta of 0.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.08 and a current ratio of 1.11.
Chemed (NYSE:CHE – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $6.75 earnings per share for the quarter, beating analysts’ consensus estimates of $6.44 by $0.31. The firm had revenue of $690.94 million during the quarter, compared to analysts’ expectations of $685.04 million. Chemed had a net margin of 10.61% and a return on equity of 35.18%. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.27 earnings per share. Sell-side analysts anticipate that Chemed Corporation will post 24.05 earnings per share for the current fiscal year.
Chemed Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, December 4th. Stockholders of record on Monday, November 16th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, November 16th. Chemed’s dividend payout ratio (DPR) is presently 13.40%.
Chemed Company Profile
Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services. VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.
Further Reading
- Five stocks we like better than Chemed
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
